Clinical Trials Logo

Hyperkalemia clinical trials

View clinical trials related to Hyperkalemia.

Filter by:

NCT ID: NCT00868439 Completed - Heart Failure Clinical Trials

Evaluation of Patiromer in Heart Failure Patients

PEARL-HF
Start date: April 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study was to assess the effects of patiromer on serum potassium participants with heart failure. This study also assessed the safety and tolerability of patiromer in participants with heart failure.

NCT ID: NCT00290160 Completed - Hyperkalemia Clinical Trials

Early Protein Supplementation on Prevention of Hyperkalemia

Start date: December 2002
Phase: N/A
Study type: Interventional

Evaluate if early protein supplementation decreases the incidence of hyperkalemia in Extremely Low Birth Weight Infants (babies less than 1,000 grams birth weight).

NCT ID: NCT00162487 Recruiting - Clinical trials for Chronic Renal Failure

Genetic Determinants of the Hypokalemic and Hyperglycemic Effect of Albuterol Inhalation

Start date: August 2002
Phase: N/A
Study type: Interventional

Several studies have indicated that albuterol administered either intravenously or by inhalation can significantly reduce plasma potassium concentration in patients suffering from chronic renal failure.In conjunction with the decrease in potassium concentration a modest rise in glucose concentration is usually noted. These metabolic effects are characterized by rapid onset occurring as early as 3-5 minutes following salbutamol administration and lasting for at least 1 hour. The role played by ß2AR polymorphisms in determining the bronchial and vascular response to ß2AR agonist drugs, have been confirmed by several studies. The purpose of the present study is to examine possible causal relationships between genetically based alteration in the structure of ß2AR and the metabolic effects of inhaled albuterol.